10:33 AM EST - Correvio Pharma Corp. : Has received independent regulatory and legal opinions that Brinavess® (vernakalant hydrochloride, IV) may qualify for up to a five-year patent extension from the U.S. Patent and Trademark Office. Brinavess® is Correvio's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation, for which it will be resubmitting a New Drug Application to the U.S. Food and Drug Administration during the second quarter of 2019. Correvio Pharma Corp.
shares T.CORV are trading up $0.06 at $4.75.
